Mireia brings over 20 years of international pharmaceutical experience with roles of increasing responsibility in R&D and business development/ licensing (BD&L). Prior to joining Numab as Chief Business Officer, Mireia held a CBO role at Topas Therapeutics and global senior management positions at leading pharmaceutical companies, including Novartis in Switzerland and Bristol Myers-Squibb in the US. She also held roles in R&D at Janssen (Johnson & Johnson) in the US and Almirall SA in Barcelona (Spain). In her various positions, she has contributed to the expansion of strategic deals and partnering activities across immunology, oncology, and cardiometabolic disease areas. Mireia holds a PhD in biochemistry and molecular biology from the University of Barcelona, Spain.

Tea joined Numab in 2011, establishing Numab’s antibody discovery platform. From 2004 to 2011 Tea was Head of PK & PD at ESBATech where she was responsible for the pharmacodynamic and pharmacokinetic characterization of antibody fragments. She led preclinical discovery and development projects in the field of ophthalmology and immuno-oncology. Tea was instrumental in the discovery and preclinical development of brolucizumab/Beovu®, a best-in-class anti-VEGF fragment for the treatment of age-related macular edema, launched by Novartis. She graduated with a degree in Molecular Biology and Immunology and obtained her PhD in Molecular Biology from the University of Zurich.

Roland joined Numab in 2011. Prior to his current position, Roland worked for 7 years in the banking industry in Switzerland and Asia with positions in marketing, customer experience management, business process management and information technology. Roland holds a Licenciate in Economics and Business Administration and a Certificate of Advanced Studies in Corporate Finance, both from the University of Zurich.

Sebastian is Numab’s Chief Operating Officer and oversees the project management, quality assurance, human resource, and support functions. He joined Numab in 2012 to head the engineering and process development group. He is an inventor of the λ-Cap™ stable scaffold and MATCH™ multispecific format technologies underlying Numab’s pipeline assets. Before joining Numab, Sebastian was responsible for DSP and analytics development at ESBATech, focusing on novel scFv drug candidates in Phase I/II of clinical development, including brolucizumab/Beovu®, a best-in-class anti-VEGF fragment for the treatment of age-related macular edema, launched by Novartis. Prior to this, Sebastian was a bioprocess development group leader at Cytos Biotechnology. Sebastian graduated with a degree in Biochemistry from the University of Hamburg and received his PhD and eMBA from the University of Zurich.

James is General Counsel of Numab and Secretary of the Numab Board of Directors. Prior to joining Numab in October 2021, James served as General Counsel for Waypoint Capital (US) and its healthcare fund Gurnet Point Capital from 2016 to 2021, and served on the board of Boston Pharmaceuticals, Tremeau Pharmaceuticals and Auregen BioTherapeutics. From 2004 to 2016, James held senior legal leadership positions at Serono International and, following Merck’s acquisition of Serono, Merck KGaA, serving as Head of Legal for Serono R&D, Merck’s corporate venture fund Merck Ventures, Merck Biopharma Global Business Development and Merck Biosimilars. James received his Juris Doctor degree from NYU School of Law and his Bachelor of Arts degree from State University of New York at Albany.

Dan joined Numab in 2019. He began his career in industry at Oxford Glycosciences, UK in 2002 developing antibody-based therapeutics in the field of Oncology. He then spent 7 years at Genzyme, a Sanofi company, where he helped to establish the antibody therapeutics group of Genzyme in Cambridge, UK. He led the protein engineering and molecular biology teams and was responsible for leading therapeutic programs in oncology and immunology. Dan moved to Switzerland in 2012 and worked for Molecular Partners as VP, Biology and led a team responsible for the preclinical biological characterization of protein-based therapeutics in immune-oncology, oncology, immunology, and ophthalmology. He was also instrumental in collaborations with Roche, Janssen, Allergan and Immunogen. Dan holds a PhD in molecular immunology from the University of Reading and performed a postdoc at the Department of Pharmacology at the University of Oxford, where he studied signaling pathways of platelet activation.

Martin is Chief Medical Officer and leads the clinical development of Numab’s molecules. He joined the company in 2023 from Affivant, an innate immunology biotech where he also held the CMO role. Prior to this, he spent 8 years at Roche’s pRED oncology early development group at increasing levels of responsibility, where he oversaw a large number of Phase 1 trials across different modalities. Martin started his career as a physician/scientist at Basel University Hospital, where he specialized in hematology with a focus on bone marrow transplantation and practiced for over a decade. In parallel, he headed the Immunotherapy laboratory at the Department of Biomedicine.

David is the Chief Executive Officer and a co-founder of Numab. Prior to starting Numab, David was Head of Research & Development at ESBATech, where he conceived and implemented ESBATech’s antibody discovery platform. He was responsible for the discovery and preclinical development of brolucizumab/Beovu®, a best-in-class anti-VEGF fragment for the treatment of age-related macular edema, launched by Novartis. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.

Elmar joined Numab in 2020 as project leader of its development projects and is now heading the project and alliance management team at Numab. He has 20 years of project and alliance management experience in biotech and pharma, including at Serono, Merck Serono, Novo Nordisk and Molecular Partners. During this time Elmar brought as project leader numerous projects in oncology and inflammation into clinical development. Before moving to biotech, Elmar obtained a Master’s in biotechnology engineering from the ESBS in Strasbourg, a PhD in cellular and molecular biology from the University of Strasbourg, and performed a Postdoc at Harvard Medical School in the department of Biological Chemistry & Molecular Pharmacology.

Stefan is Numab’s Chief Technology Officer and responsible for the continued advancement of our multi-specific platform technology, as well as Numab’s discovery, engineering, and CMC efforts. Before joining Numab in 2015, Stefan worked in pharmaceutical development at CSL Behring, focusing on process development and optimization to support clinical production and upscaling. He received his degree in Biochemistry from the ETH Zurich and obtained a PhD in Structural Biology and Biochemistry from the University of Zurich. At Numab, Stefan has built a highly effective team driving platform innovation and CMC development. Stefan played a pivotal role in the discovery, rationale engineering, formulation and manufacturing of several Numab pipeline candidates subjected to clinical testing, including NM26, an anti-IL4R/IL-31 antibody acquired by Johnson & Johnson in 2024, which Numab developed as a convenient self-administrable subcutaneous product.

Lisa Beck, MD. is a Lowell A. and Carol A. Goldsmith Professor in Dermatology at the Department of Dermatology, at the University of Rochester, NY. She was the lead author of the 2014 New England Journal of Medicine dupilumab paper that set the stage for the FDA approval of this drug in March 2017. She is the Co-Director of the URMC Center for Allergic Disease Research (CADR) which was recently chosen as one of four US centers with the World Allergy Organizations Center of Excellence designation.

Thomas Bieber, MD, PhD. is a Professor for Dermatology and Allergology at the University of Bonn, Germany. He is the Chief Editor of Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology (EAACI) and he serves as a board member of several national and international societies.

Michael J. Cork, BSc MB PhD FRCP is a Professor of Dermatology at the Department of Infection, Immunity and Cardiovascular Disease at the University of Sheffield UK. He is a member of the National Institute of Clinical Excellence (NICE) clinical guideline development group for the treatment of Atopic Eczema in children.

Mette Deleuran, MD, DMSc. is a Professor and the Chairman at the Department of Dermatology at the Aarhus University Hospital, in Aarhus, Denmark. She specializes in dermatology with a focus on atopic dermatitis and inflammatory skin diseases. Her research includes basic science, epidemiology and clinical studies and she is a founding member of the International Society of Atopic Dermatitis.

Robert L. Ferris, M.D., Ph.D. is the Director of the UPMC Hillman Cancer Center of the University of Pittsburgh, where he is a Professor of Oncology and Immunology and a Co-Director of the Tumor Microenvironment Center. Robert is a leading expert in the immuno-biology and treatment of head and neck cancer. He has been the principal investigator in multiple Phase I-III clinical trials and his research is focused on cellular immune mechanisms of natural killer (NK) cells, dendritic cells, and T lymphocyte activation against head and neck cancer tumor antigens.

Matthew Galsky, M.D., is a Professor of Medicine, Hematology and Medical Oncology and a Professor of Urology at the Icahn School of Medicine at the Mount Sinai Health Systems hospitals in New York. Matthew also serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute. He specializes in the care of patients with genitourinary malignancies (i.e. bladder and kidney cancer). His research focuses on the development of novel treatments for these cancers, and he uses team-science based approaches to understand sensitivity and resistance to such therapies.

David Hong, M.D., is a Professor of Medicine and the Associate Vice President of Clinical Research at MD Anderson Cancer Center. Throughout his career, he has developed an interest in studying the efficacy of novel drug combinations in patients with solid tumors. Recently his research endeavors have focused on developing personalized therapies for patients, whose tumors bear specific genetic mutations/amplifications and combining targeted therapies with immunotherapies.

Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies. Earlier in his career, he contributed to seminal discoveries in the function Natural Killer cells, and T-cell co-stimulation via CD137 (4-1BB). Ignacio has been awarded the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a CRI research award. He has served on advisory boards of Bristol Myers-Squibb, Roche-Genentech, AstraZeneca, Merck Serono and Boehringer Ingelheim, and holds research grants by Pfizer, Bristol Myers Squibb, and Alligator.

Mario Sznol, M.D., is a Professor of Medicine (Medical Oncology). Mario, formerly with the National Cancer Institute, has an international reputation in cancer drug development. His expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.